New study evaluates the safety profile of the BNT162b2 vaccine in New Zealand
News Medical, Jan 24 2023
In a recent study posted to the Preprints with The Lancet* server, researchers determined the association between adverse events of special interest (AESIs) following BNT162b2 vaccination, a coronavirus disease 20…
New study evaluates the safety profile of the BNT162b2 vaccine in New Zealand
News Medical, Jan 24 2023
In a recent study posted to the Preprints with The Lancet* server, researchers determined the association between adverse events of special interest (AESIs) following BNT162b2 vaccination, a coronavirus disease 2019 (COVID-19) vaccine based on the messenger ribonucleic acid (mRNA) technology.
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication.
Study findings
The risk of myocarditis and pericarditis was low in those under 19 years old, with more than five and two events per 100,000 persons after the second and first vaccine dose(s), respectively. Since studies have shown that the risk of myocarditis following COVID-19 is much greater than after vaccination with an mRNA vaccine, its benefits continue to offset the risk of the disease.
Further, the researchers noted a statistically marked increase in the incidence of acute kidney injury (AKI) following first and second doses of BNT1262b in all age bands except five to 19-year-olds. Most patients who reported AKI were >65 years, and over 50% of them had pre-existing diseases that could have contributed to AKI (e.g., diabetes). Thus, more research alone could justify the observed association, if there is any.
Journal references:
Preliminary scientific report. Walton, Muireann, and Pletzer, Vadim and Teunissen, Thomas and Lumley, Thomas and Hanlon, Timothy. (2023). Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNtech) in Aotearoa New Zealand. SSRN. https://ssrn.com/abstract=4329970
https://www.news-medical.net/news/20230124/New-study-evaluates-the-safety-profile-of-the-BNT162b2-vaccine-in-New-Zealand.aspx
New study evaluates the safety profile of the BNT162b2 vaccine in New Zealand
News Medical, Jan 24 2023
In a recent study posted to the Preprints with The Lancet* server, researchers determined the association between adverse events of special interest (AESIs) following BNT162b2 vaccination, a coronavirus disease 2019 (COVID-19) vaccine based on the messenger ribonucleic acid (mRNA) technology.
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication.
Study findings
The risk of myocarditis and pericarditis was low in those under 19 years old, with more than five and two events per 100,000 persons after the second and first vaccine dose(s), respectively. Since studies have shown that the risk of myocarditis following COVID-19 is much greater than after vaccination with an mRNA vaccine, its benefits continue to offset the risk of the disease.
Further, the researchers noted a statistically marked increase in the incidence of acute kidney injury (AKI) following first and second doses of BNT1262b in all age bands except five to 19-year-olds. Most patients who reported AKI were >65 years, and over 50% of them had pre-existing diseases that could have contributed to AKI (e.g., diabetes). Thus, more research alone could justify the observed association, if there is any.
Journal references:
Preliminary scientific report. Walton, Muireann, and Pletzer, Vadim and Teunissen, Thomas and Lumley, Thomas and Hanlon, Timothy. (2023). Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNtech) in Aotearoa New Zealand. SSRN. https://ssrn.com/abstract=4329970
https://web.archive.org/web/20230121193613/https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4329970
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNtech) in Aotearoa New Zealand, Wakton et al, 20 Jan 2023
"An increased incidence of acute kidney injury (AKI) was observed following the first (1.6 (1.5– 1.6)) and second (1.7 (1.6– 1.7)) dose of BNT162b2."
https://www.zerohedge.com/medical/new-zealand-fudged-data-how-kidneys-fare-after-covid-vaccines